Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company reported having no debt at the end of Q3, with a high cash balance of Rs. 3,000 crore. Incremental cash is expected after completion of the TAN project, but future capital allocation focus is on strategic growth areas like global phosphate supply chains rather than fundraising. The company seems focused on internal cash flows and investments, e.g., CAPEX of Rs. 357 crore in the current year mostly towards the TAN project. Discussions about securing phosphate supply

Any current/future capex/capital investment/strategic investment?

TAN (Technical Ammonium Nitrate) Project: Commercial production expected January 2026; cumulative spend Rs. 541 crore as of January 2025. Positive contribution anticipated in FY '27. IMACID Expansion: Phosphoric acid capacity expanding from 5 lakh to 7 lakh metric tons; total investment $173 million, expected completion by FY '27-'28. Sulphuric Acid Plant Study: To support IMACID expansion; cost finalization ongoing. Biologicals Pipeline: Partnership with TERI to develop new biological product lines with exclusive global rights, starting research March 2025; aim for Rs. 300-400 crore sales by

Future growth expectations in sales/revenue/volumes?

Crop Protection Chemicals (CPC) & Specialty Nutrients (SN) revenues grew 26% YoY in Q3 FY25; ambitions to introduce 3-4 new products annually to sustain growth. Biological products pipeline expected to generate Rs. 300-400 crore in sales by FY 26-29 driven by CFCL-TERI Center for Excellence research. Expansion into hybrid and research variety seeds (wheat, millet, maize, mustard) expected to start sales in Kharif FY25 onwards. TAN project commissioning targeted by January 2026 with positive contribution expected in FY27. IMACID JV Phosphoric Acid expansion to 7 lakh metric tons capacity by FY2

Future growth expectations in earnings/operating earnings/profits/EPS?

Chambal Fertilisers targets continued growth in Crop Protection Chemicals (CPC) and Specialty Nutrients (SN), aiming to add 3-4 new products annually, projecting Rs. 1,750 crore revenue in CPC by FY'27. Biologicals segment is expected to reach Rs. 300-400 crore sales by FY'29 with a strong product pipeline from TERI research. TAN project commercial production begins January 2026, with positive contribution expected in FY'27. Utilization above 80-85% anticipated for threshold IRR of ~14-15%. Urea volumes stable with expected Q4 production impacted by planned shutdown; overall EBITDA growt

IN US

Sale is live|00:00:00left today

Chambal Fertilisers & Chemicals LtdQ4 FY26Fertilizers & Agrochemicals

Chambal Fertilisers & Chemicals Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹476P/E: 9.2Market Cap: ₹18.0K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Crop Protection Chemicals (CPC) & Specialty Nutrients (SN) revenues grew 26% YoY in Q3 FY25; ambitions to introduce 3-4 new products annually to sustain growth.
→Biological products pipeline expected to generate Rs. 300-400 crore in sales by FY 26-29 driven by CFCL-TERI Center for Excellence research.
→Expansion into hybrid and research variety seeds (wheat, millet, maize, mustard) expected to start sales in Kharif FY25 onwards.
→TAN project commissioning targeted by January 2026 with positive contribution expected in FY27.
→IMACID JV Phosphoric Acid expansion to 7 lakh metric tons capacity by FY27-28 to enhance non-urea segment.
→Global phosphate supply chain initiatives planned to strengthen Chambal's global positioning.
→Overall strategy aims for steady revenue and volume growth, with focus on innovative products and portfolio expansion.

Margin guidance

Category 3

→Chambal Fertilisers targets continued growth in Crop Protection Chemicals (CPC) and Specialty Nutrients (SN), aiming to add 3-4 new products annually, projecting Rs. 1,750 crore revenue in CPC by FY'27.
→Biologicals segment is expected to reach Rs. 300-400 crore sales by FY'29 with a strong product pipeline from TERI research.
→TAN project commercial production begins January 2026, with positive contribution expected in FY'27. Utilization above 80-85% anticipated for threshold IRR of ~14-15%.
→Urea volumes stable with expected Q4 production impacted by planned shutdown; overall EBITDA growth driven by energy efficiency (improvement of 3%).
→IMACID phosphoric acid expansion underway, projected completion by FY'27-28, expected to strengthen global phosphate supply position.
→Overall, the company aims to sustain and improve profitability with strategic inorganic moves, product portfolio expansions, and operational efficiencies.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company reported having no debt at the end of Q3, with a high cash balance of Rs. 3,000 crore.
→Incremental cash is expected after completion of the TAN project, but future capital allocation focus is on strategic growth areas like global phosphate supply chains rather than fundraising.
→The company seems focused on internal cash flows and investments, e.g., CAPEX of Rs. 357 crore in the current year mostly towards the TAN project.
→Discussions about securing phosphate supply chains may lead to investments, but no timelines or funding details are shared.
→Overall, the company appears financially strong and is not indicating the need for external fundraising at this time.

Order book

The provided transcript does not explicitly mention any details regarding the current or expected order book or pending orders for Chambal Fertilisers and Chemicals Limited. The discussion primarily focuses on: - Product pipeline and market reintroduction plans (e.g., Chambal brand reintroduction). - Ongoing and upcoming projects such as the Technical Ammonium Nitrate (TAN) plant and IMACID capacity expansion. - Focus on biologicals and specialty nutrients with projected sales targets. - Crop protection business growth and volume/pricing dynamics. - Capital allocation and supply chain strategies for phosphates. - Operational performance and financial results details. No direct information on specific order backlog or pending order volumes is provided in the transcript.

Capex plans

Yes

→TAN (Technical Ammonium Nitrate) Project: Commercial production expected January 2026; cumulative spend Rs. 541 crore as of January 2025. Positive contribution anticipated in FY '27.
→IMACID Expansion: Phosphoric acid capacity expanding from 5 lakh to 7 lakh metric tons; total investment $173 million, expected completion by FY '27-'28.
→Sulphuric Acid Plant Study: To support IMACID expansion; cost finalization ongoing.
→Biologicals Pipeline: Partnership with TERI to develop new biological product lines with exclusive global rights, starting research March 2025; aim for Rs. 300-400 crore sales by 2028-29.
→Seeds Business: Entry into hybrid and research variety seeds (wheat, mustard, millet, maize) starting Kharif FY '25.
→Global Phosphate Supply Chain: Exploring inorganic moves and global investments to secure phosphate supply.

How does Chambal Fertilisers & Chemicals Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Chambal Fertilisers & Chemicals Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Chambal Fertilisers & Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio